ISRCTN80829286
Completed
Not Applicable
A 3.5 year Randomised Controlled Study on Bone Mineral Density and Fractures in Crohn?s Disease comparing Calcium & Vitamin D or additional Sodium-Fluoride or Ibandronate
niversity Hospital Ulm (Universitätsklinikum Ulm) (Germany)0 sites200 target enrollmentApril 14, 2010
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity Hospital Ulm (Universitätsklinikum Ulm) (Germany)
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Crohn's disease
- •2\. Reduced bone mineral density (T\-score \< \-1,0\)
Exclusion Criteria
- •1\. Age \<18 years
- •2\. Chronic renal insufficiency (creatinine \>1,5mg/dl)
- •3\. Known primary hypo\- or hyperparathyroidism
- •4\. Untreated thyroid disease
- •5\. Any known medication, e.g. previous treatment with either sodium\-fluoride or bisphosphonates
- •6\. Condition affecting BMD other than glucocorticoids
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Histomorphometric and immunohistochemical evaluation of beta-tricalcium phosphate of different particles dimensions in maxillary sinus floor elevation: a randomized clinical studyStomatognathic diseasesMaxillary sinusBone substitutesBone resorptionA04.531.621.578D25.130.325C05.116.264RBR-63c3gnFaculdade de Odontologia de Araçatuba
Completed
Not Applicable
A clinical study to evaluate the efficacy of bone-modyfying agent for the patients of prostate cancer.JPRN-UMIN000015126Department of Urology, Keio University School of Medicine
Completed
Phase 3
A Randomised Controlled Trial of a Marinova Seaweed Extract on OsteoarthritisOsteoarthritisMusculoskeletal - OsteoarthritisACTRN12613000654752Marinova Pty Ltd130
Active, not recruiting
Phase 1
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2021-000452-19-BGObsEva S.A.400
Active, not recruiting
Phase 1
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2021-000452-19-PLObsEva S.A.400